Traitement des rechutes tardives du cancer de l’ovaire

Abstract

Despite large improvements in treatment efficacy, the cure rate of ovarian cancer has not radically changed. Relapses both remain frequent and are still synonymous with chronic disease. Most of them are platinum-sensitive, and can be successfully treated with successive lines of chemotherapy. Surgery may have a role to play but its real impact, population selection criteria, and adequate timing still have to be established. Regarding medical treatments, the availability of new targeted therapeutics, such as bevacizumab and olaparib, complicates decision making. Moreover, allergic drug reactions to platins worsen treatment management. In practice, treatment decision making integrates patient profiles and wishes, types and numbers of previous medical treatments along with BRCA status.

Keywords: Allergie; Bevacizumab; Bévacizumab; Chemotherapy; Chimiothérapie; Chirurgie; Drug reaction; Olaparib; Platinum sensitive relapse; Rechute platine sensible; Surgery.